Search

Your search keyword '"Harding, James J."' showing total 589 results
Start Over Author "Harding, James J."
589 results on '"Harding, James J."'

2. ASO Visual Abstract: Has Management of Intrahepatic Cholangiocarcinoma Evolved with the Evidence? Trends and Practice Patterns from the National Cancer Database

Author

Schleimer, Lauren E., Kalvin, Hannah L., Ellis, Ryan J., Kingham, T. Peter, Soares, Kevin C., D’Angelica, Michael I., Balachandran, Vinod P., Drebin, Jeffrey, Cercek, Andrea, Abou-Alfa, Ghassan K., O’Reilly, Eileen M., Harding, James J., Gönen, Mithat, Wei, Alice C., and Jarnagin, William R.

Published
2024
Full Text
View/download PDF

3. Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma

Author

Franssen, Stijn, Holster, Jessica J., Jolissaint, Joshua S., Nooijen, Lynn E., Cercek, Andrea, D’Angelica, Michael I., Homs, Marjolein Y. V., Wei, Alice C., Balachandran, Vinod P., Drebin, Jeffrey A., Harding, James J., Kemeny, Nancy E., Kingham, T. Peter, Klümpen, Heinz-Josef, Mostert, Bianca, Swijnenburg, Rutger-Jan, Soares, Kevin C., Jarnagin, William R., and Groot Koerkamp, Bas

Published
2024
Full Text
View/download PDF

5. ASO Visual Abstract: Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma

Author

Franssen, Stijn, Holster, Jessica J., Jolissaint, Joshua S., Nooijen, Lynn E., Cercek, Andrea, D’Angelica, Michael I., Homs, Marjolein Y. V., Wei, Alice C., Balachandran, Vinod P., Drebin, Jeffrey A., Harding, James J., Kemeny, Nancy E., Kingham, T. Peter, Klümpen, Heinz-Josef, Mostert, Bianca, Swijnenburg, Rutger-Jan, Soares, Kevin C., Jarnagin, William R., and Groot Koerkamp, Bas

Published
2024
Full Text
View/download PDF

7. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

Author

Harding, James J., Piha-Paul, Sarina A., Shah, Ronak H., Murphy, Jessica J., Cleary, James M., Shapiro, Geoffrey I., Quinn, David I., Braña, Irene, Moreno, Victor, Borad, Mitesh, Loi, Sherene, Spanggaard, Iben, Park, Haeseong, Ford, James M., Arnedos, Mónica, Stemmer, Salomon M., de la Fouchardiere, Christelle, Fountzilas, Christos, Zhang, Jie, DiPrimeo, Daniel, Savin, Casey, Duygu Selcuklu, S., Berger, Michael F., Eli, Lisa D., Meric-Bernstam, Funda, Jhaveri, Komal, Solit, David B., and Abou-Alfa, Ghassan K.

Published
2023
Full Text
View/download PDF

8. Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma

Author

McIntyre, Sarah M., Preston, William A., Walch, Henry, Sharib, Jeremy, Kundra, Ritika, Sigel, Carlie, Lidsky, Michael E., Allen, Peter J., Morse, Michael A., Chen, Wei, Cercek, Andrea, Harding, James J., Abou-Alfa, Ghassan K., OʼReilly, Eileen M., Park, Wungki, Balachandran, Vinod P., Drebin, Jeffrey, Soares, Kevin C., Wei, Alice, Kingham, T. Peter, DʼAngelica, Michael I., Iacobuzio-Donahue, Christine, and Jarnagin, William R.

Published
2024
Full Text
View/download PDF

11. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

Author

Harding, James J, K., Richard, Yaqubie, Amin, Cleverly, Ann, Zhao, Yumin, Gueorguieva, Ivelina, Lahn, Michael, Benhadji, Karim A, Kelley, Robin K, and Abou‐Alfa, Ghassan K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Rare Diseases, Clinical Research, Digestive Diseases, Liver Disease, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular, Female, Humans, Liver Neoplasms, Male, Maximum Tolerated Dose, Middle Aged, Nausea, Prospective Studies, Pyrazoles, Quinolines, Receptor, Transforming Growth Factor-beta Type I, Response Evaluation Criteria in Solid Tumors, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-2, Vomiting, alpha-Fetoproteins, galunisertib, HCC, hepatocellular carcinoma, Phase 1, ramucirumab, TGF&#8208, &#946, VEGF, TGF-β, Biochemistry and Cell Biology, Oncology and carcinogenesis
Abstract

BackgroundPreclinical data suggest that vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-β signaling interact to stimulate angiogenesis and suppress antitumor immune responses. Thus, combined inhibition of both pathways may offer greater antitumor activity compared with VEGF-targeted antiangiogenic monotherapy against hepatocellular carcinoma (HCC).MethodsThis is a multicenter, open-label, phase 1b study of galunisertib, an inhibitor of TGF-β receptor 1, and ramucirumab, an anti-VEGF receptor 2 antibody, in patients with advanced HCC aiming to define the maximum tolerated dose (MTD). Secondary objectives included safety, pharmacokinetics (PK), antitumor efficacy, and plasma alpha-fetoprotein and TGF-β kinetics. Dose escalation employed a 3 + 3 design. Patients received galunisertib at 80 mg (cohort 1) or 150 mg (cohort 2) orally twice a day on days 1-14 of a 28-day cycle combined with ramucirumab 8 mg/kg intravenously every 2 weeks.ResultsEight patients were enrolled: three in cohort 1 and five in cohort 2 (two patients were unevaluable due to rapid disease progression and replaced). No dose-limiting toxicities were observed. Treatment-related adverse events (AEs) of any grade in ≥2 patients included nausea (25%) and vomiting (25%). There was one Grade 3 treatment-related AE, a cerebrovascular accident possibly related to ramucirumab. Galunisertib exposure was dose-proportional and not affected by ramucirumab. The RECIST version 1.1 objective response rate and disease control rate were 0% and 12.5%, respectively.ConclusionCombination therapy was safe and tolerable and displayed favorable PK. The MTD was established at galunisertib at 150 mg orally twice a day and ramucirumab 8 mg/kg intravenously every 2 weeks. The results do not support the preclinical hypothesis that blocking TGFβ signaling enhances efficacy of VEGF-targeted therapy; thus further clinical development was halted for the combination of galunisertib and ramucirumab.

Published
2021

12. Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma

Author

Harding, James J, Kelley, Robin K, Tan, Benjamin, Capanu, Marinela, Kinh, Gian, Shia, Jinru, Chou, Joanne F, Ferrer, Christine S, Boussayoud, Chayma, Muenkel, Kerri, Yarmohammadi, Hooman, Dika, Imane El, Khalil, Danny N, Ruiz, Carmen, Rodriguez‐Lee, Mariam, Kuhn, Peter, Wilton, John, Iyer, Renuka, and Abou‐Alfa, Ghassan K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Liver Cancer, Clinical Trials and Supportive Activities, Rare Diseases, Liver Disease, Clinical Research, Digestive Diseases, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Niacinamide, Nitriles, Phenylthiohydantoin, Phenylurea Compounds, Sorafenib, Treatment Outcome, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Lessons learnedAndrogen receptor as assessed by immunohistochemistry is expressed in a high proportion of patients with hepatocellular carcinoma (HCC). Enzalutamide at 160 mg orally daily is safe and tolerable in patients with advanced HCC but has no single-agent antitumor activity. Enzalutamide, a CYP3A4 inducer, at a standard dose of 160 mg reduces the exposure of sorafenib, a CYP3A4 substrate. Enzalutamide and sorafenib is safe and tolerable in patients with advanced HCC, but the addition of enzalutamide to sorafenib did not enhance the antitumor activity of sorafenib.BackgroundAndrogen receptor (AR) interference is deleterious to hepatocellular carcinoma (HCC) in preclinical models.MethodsThis is a multicenter, phase Ib study of enzalutamide ± sorafenib in patients with advanced HCC. In part 1, a 3 + 3 dose de-escalation design with expansion established the recommended phase II dose (RP2D) of enzalutamide in patients in whom sorafenib treatment had failed. In part 2, a 3 + 3 dose escalation with expansion established the safety of enzalutamide with sorafenib in treatment-naive patients with HCC. Secondary objectives included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), pharmacokinetics (PK), and determination of AR expression by immunohistochemistry. A 7-day run-in with sorafenib alone in part 2 allowed assessment of the impact of enzalutamide on sorafenib pharmacokinetics.ResultsIn part 1, 16 patients received enzalutamide 160 mg daily. No dose-limiting toxicity (DLT) occurred; 1 patient required dose reduction. Responses were not observed; median PFS and OS were 1.8 (95% confidence interval [CI]: 1.6-3.6) and 7 (95% CI: 3.6 to not reached [NR]) months, respectively. In part 2, patients received sorafenib 400 mg daily (4) or twice a day (8) both with enzalutamide at the recommended phase II dose-no DLTs were observed. ORR was 10% (95% CI: 0.3-44.5), and median PFS and OS were 2.9 (95% CI: 1.6 to NR) and 6.7 (95% CI: 4.6 to NR) months, respectively. Enzalutamide reduced sorafenib exposure by 60%. Tumor AR expression did not associate with outcome.ConclusionEnzalutamide is ineffective in HCC; further development is not supported by this study.

Published
2020

13. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

Author

Abou-Alfa, Ghassan, Alfonso, Jorge Adeva, Aglietta, Massimo, Baron, Ari, Beg, Muhammad, Aguirre, Paula Carrasco, Chen, Eric, Cheng, Ying, Gracián, Antonio Cubillo, Dahan, Laetitia, De Braud, Filippo, Fenocchio, Elisabetta, Gbolohon, Olumide, Gillmore, Roopinder, Jary, Marine, Javle, Milind, Jiang, Yixing, Kang, Jung Hun, King, Gentry George, Kundranda, Madappa, Layos, Laura, Li, Daneng, Liang, Tingbo, Lonardi, Sara, Marathe, Omkar, Mondaca, Sebastian, Martin, Andrés J. Muñoz, Park, Joon Oh, Pazo Cid, Roberto, Fernandez, Paula Ribera, Rimassa, Lorenza, Alonso, Rosa Rodriguez, Sadeghi, Saeed, Scott, Aaron, Tan, Benjamin, Tougeron, David, Yan, Qiang, Yin, Xiaoyu, Zhao, Haitao, Harding, James J, Fan, Jia, Oh, Do-Youn, Choi, Hye Jin, Kim, Jin Won, Chang, Heung-Moon, Bao, Lequn, Sun, Hui-Chuan, Macarulla, Teresa, Xie, Feng, Metges, Jean-Phillippe, Ying, Jie'er, Bridgewater, John, Lee, Myung-Ah, Tejani, Mohamedtaki A, Chen, Emerson Y, Kim, Dong Uk, Wasan, Harpreet, Ducreux, Michel, Bao, Yuanyuan, Boyken, Lisa, Ma, Jiafang, Garfin, Phillip, and Pant, Shubham

Published
2023
Full Text
View/download PDF

14. Second‐line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes

Author

Lowery, Maeve A, Goff, Laura W, Keenan, Bridget P, Jordan, Emmet, Wang, Rui, Bocobo, Andrea G, Chou, Joanne F, O’Reilly, Eileen M, Harding, James J, Kemeny, Nancy, Capanu, Marianela, Griffin, Ann C, McGuire, Joseph, Venook, Alan P, Abou‐Alfa, Ghassan K, and Kelley, Robin K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Cancer, Digestive Diseases, Digestive Diseases - (Gallbladder), Liver Disease, Clinical Trials and Supportive Activities, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Retreatment, Retrospective Studies, Treatment Failure, Treatment Outcome, Young Adult, biliary cancer, bile duct cancer, chemotherapy, cholangiocarcinoma, gallbladder cancer, second line, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundAlthough gemcitabine plus platinum chemotherapy is the established first-line regimen for advanced biliary cancer (ABC), there is no standard second-line therapy. This study evaluated current practice and outcomes for second-line chemotherapy in patients with ABC across 3 US academic medical centers.MethodsInstitutional registries were reviewed to identify patients who had received second-line chemotherapy for ABC from April 2010 to March 2015 along with their demographics, diagnoses and staging, treatment histories, and clinical outcomes. Overall survival from the initiation of second-line chemotherapy (OS2) was estimated with Kaplan-Meier methods.ResultsThis study identified 198 patients with cholangiocarcinoma (intrahepatic [61.1%] or extrahepatic [14.1%]) or gallbladder carcinoma (24.8%); 52% received at least 3 lines of systemic chemotherapy. The median OS2 was 11 months (95% confidence interval [CI], 8.8-13.1 months). The median OS2 for patients with intrahepatic cholangiocarcinoma was 13.4 months (95% CI, 10.7-17.8 months), which was longer than that for patients with extrahepatic cholangiocarcinoma (6.8 months; 95% CI, 5-10.6 months) or gallbladder carcinoma (9.4 months; 95% CI, 7.2-12.3 months; P = .018). The median time to second-line treatment failure was 2.2 months (95% CI, 1.8-2.7 months), and it was similar across tumor locations (P = .60).ConclusionsIn this large cohort of patients with ABC treated across 3 academic medical centers after the failure of first-line chemotherapy, the time to treatment failure on standard therapies was short, although the median OS2 was longer than has been reported previously, and more than half of the patients received additional lines of treatment. This multicenter collaboration represents the largest cohort studied to date of second-line chemotherapy for ABC and provides a contemporary benchmark for future clinical trials.

Published
2019

17. Outcomes of Y90 Radioembolization for Hepatocellular Carcinoma in Patients Previously Treated with Transarterial Embolization

Author

Zhao, Ken, primary, Son, Sam, additional, Karimi, Anita, additional, Marinelli, Brett, additional, Erinjeri, Joseph P., additional, Alexander, Erica S., additional, Sotirchos, Vlasios S., additional, Harding, James J., additional, Soares, Kevin C., additional, Ziv, Etay, additional, Covey, Anne, additional, Sofocleous, Constantinos T., additional, and Yarmohammadi, Hooman, additional

Published
2024
Full Text
View/download PDF

18. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

Author

Goyal, Lipika, Shi, Lei, Liu, Leah Y, de la Cruz, Ferran Fece, Lennerz, Jochen K, Raghavan, Srivatsan, Leschiner, Ignaty, Elagina, Liudmila, Siravegna, Giulia, Ng, Raymond WS, Vu, Phuong, Patra, Krushna C, Saha, Supriya K, Uppot, Raul N, Arellano, Ron, Reyes, Stephanie, Sagara, Takeshi, Otsuki, Sachie, Nadres, Brandon, Shahzade, Heather A, Dey-Guha, Ipsita, Fetter, Isobel J, Baiev, Islam, Van Seventer, Emily E, Murphy, Janet E, Ferrone, Cristina R, Tanabe, Kenneth K, Deshpande, Vikram, Harding, James J, Yaeger, Rona, Kelley, Robin K, Bardelli, Alberto, Iafrate, A John, Hahn, William C, Benes, Cyril H, Ting, David T, Hirai, Hiroshi, Getz, Gad, Juric, Dejan, Zhu, Andrew X, Corcoran, Ryan B, and Bardeesy, Nabeel

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Genetics, Adenosine Triphosphate, Adult, Aged, Cell Line, Tumor, Cholangiocarcinoma, Circulating Tumor DNA, Drug Resistance, Neoplasm, Female, Humans, Male, Middle Aged, Mutation, Oncogene Proteins, Fusion, Phenylurea Compounds, Protein Kinase Inhibitors, Pyrimidines, Receptor, Fibroblast Growth Factor, Type 2, Signal Transduction, Structure-Activity Relationship, Tomography, X-Ray Computed, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

ATP-competitive fibroblast growth factor receptor (FGFR) kinase inhibitors, including BGJ398 and Debio 1347, show antitumor activity in patients with intrahepatic cholangiocarcinoma (ICC) harboring activating FGFR2 gene fusions. Unfortunately, acquired resistance develops and is often associated with the emergence of secondary FGFR2 kinase domain mutations. Here, we report that the irreversible pan-FGFR inhibitor TAS-120 demonstrated efficacy in 4 patients with FGFR2 fusion-positive ICC who developed resistance to BGJ398 or Debio 1347. Examination of serial biopsies, circulating tumor DNA (ctDNA), and patient-derived ICC cells revealed that TAS-120 was active against multiple FGFR2 mutations conferring resistance to BGJ398 or Debio 1347. Functional assessment and modeling the clonal outgrowth of individual resistance mutations from polyclonal cell pools mirrored the resistance profiles observed clinically for each inhibitor. Our findings suggest that strategic sequencing of FGFR inhibitors, guided by serial biopsy and ctDNA analysis, may prolong the duration of benefit from FGFR inhibition in patients with FGFR2 fusion-positive ICC. SIGNIFICANCE: ATP-competitive FGFR inhibitors (BGJ398, Debio 1347) show efficacy in FGFR2-altered ICC; however, acquired FGFR2 kinase domain mutations cause drug resistance and tumor progression. We demonstrate that the irreversible FGFR inhibitor TAS-120 provides clinical benefit in patients with resistance to BGJ398 or Debio 1347 and overcomes several FGFR2 mutations in ICC models.This article is highlighted in the In This Issue feature, p. 983.

Published
2019

19. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Author

Yau, Thomas, Park, Joong-Won, Finn, Richard S, Cheng, Ann-Lii, Mathurin, Philippe, Edeline, Julien, Kudo, Masatoshi, Harding, James J, Merle, Philippe, Rosmorduc, Olivier, Wyrwicz, Lucjan, Schott, Eckart, Choo, Su Pin, Kelley, Robin Kate, Sieghart, Wolfgang, Assenat, Eric, Zaucha, Renata, Furuse, Junji, Abou-Alfa, Ghassan K, El-Khoueiry, Anthony B, Melero, Ignacio, Begic, Damir, Chen, Gong, Neely, Jaclyn, Wisniewski, Tami, Tschaika, Marina, and Sangro, Bruno

Published
2022
Full Text
View/download PDF

23. Supplementary Figure 5 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Author

Garmezy, Benjamin, primary, Borad, Mitesh J., primary, Bahleda, Rastilav, primary, Perez, Cesar A., primary, Chen, Li-Tzong, primary, Kato, Shumei, primary, Oh, Do-Youn, primary, Severson, Paul, primary, Tam, Betty Y., primary, Quah, Cheng S., primary, and Harding, James J., primary

Published
2024
Full Text
View/download PDF

27. Supplementary Figure 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Author

Garmezy, Benjamin, primary, Borad, Mitesh J., primary, Bahleda, Rastilav, primary, Perez, Cesar A., primary, Chen, Li-Tzong, primary, Kato, Shumei, primary, Oh, Do-Youn, primary, Severson, Paul, primary, Tam, Betty Y., primary, Quah, Cheng S., primary, and Harding, James J., primary

Published
2024
Full Text
View/download PDF

28. Supplementary Figure 4 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Author

Garmezy, Benjamin, primary, Borad, Mitesh J., primary, Bahleda, Rastilav, primary, Perez, Cesar A., primary, Chen, Li-Tzong, primary, Kato, Shumei, primary, Oh, Do-Youn, primary, Severson, Paul, primary, Tam, Betty Y., primary, Quah, Cheng S., primary, and Harding, James J., primary

Published
2024
Full Text
View/download PDF

30. Supplementary Figure 3 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Author

Garmezy, Benjamin, primary, Borad, Mitesh J., primary, Bahleda, Rastilav, primary, Perez, Cesar A., primary, Chen, Li-Tzong, primary, Kato, Shumei, primary, Oh, Do-Youn, primary, Severson, Paul, primary, Tam, Betty Y., primary, Quah, Cheng S., primary, and Harding, James J., primary

Published
2024
Full Text
View/download PDF

33. Immunotherapy

Author

Al Mahmasani, Layal, primary, Harding, James J., additional, and Abou-Alfa, Ghassan, additional

Published
2024
Full Text
View/download PDF

34. Safety and feasibility of preoperative simultaneous portal vein embolization and biliary drainage in hilar cholangiocarcinoma prior to hepatectomy

Author

Soliman, Mohamed M., primary, Chevallier, Olivier, primary, Velayati, Sara, primary, Zhao, Ken, primary, Marinelli, Brett, primary, Ridouani, Fourat, primary, Karimi, Anita, primary, Covey, Anne, primary, Erinjeri, Joseph P., primary, Schattner, Mark, primary, Harding, James J., primary, Abou-Alfa, Ghassan K., primary, Wei, Alice C., primary, Soares, Kevin C., primary, Jarnagin, William, primary, and Yarmohammadi, Hooman, primary

Published
2024
Full Text
View/download PDF

35. A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma.

Author

Dayyani, Farshid, primary, Baretti, Marina, additional, Lee, Sunyoung S., additional, He, Aiwu Ruth, additional, Kim, Richard D., additional, Lin, Bruce Shih-Li, additional, Enzler, Thomas, additional, Al Hallak, Mohammed Najeeb, additional, Ulahannan, Susanna Varkey, additional, Davis, S. Lindsey, additional, Burgoyne, Adam, additional, Tweardy, David, additional, Harding, James J., additional, Kaseb, Ahmed Omar, additional, de Achaval, Sofia, additional, Alibhai, Imran, additional, and Kauh, John S., additional

Published
2024
Full Text
View/download PDF

36. Zanidatamab (zani) in previously treated HER2+ biliary tract cancer (BTC): Impact on patient-reported pain outcomes in the phase 2b HERIZON-BTC-01 study.

Author

Pant, Shubham, primary, Fan, Jia, additional, Oh, Do-Youn, additional, Choi, Hye Jin, additional, Kim, Jin Won, additional, Chang, Heung-Moon, additional, Bao, Lequn, additional, Sun, Hui-Chuan, additional, Macarulla, Teresa, additional, Xie, Feng, additional, Metges, Jean-Philippe, additional, Ying, Jie-Er, additional, Bridgewater, John A, additional, Tejani, Mohamedtaki Abdulaziz, additional, Chen, Emerson Yu-sheng, additional, Wasan, Harpreet Singh, additional, Ducreux, Michel Pierre, additional, Ma, Jiafang, additional, Garfin, Phillip M., additional, and Harding, James J., additional

Published
2024
Full Text
View/download PDF

37. Intrahepatic cholangiocarcinoma: Recurrence patterns, genomics and survival.

Author

Chandra, Pratik, primary, Song, Yi, additional, Drill, Esther N., additional, Wei, Alice Chia-Chi, additional, Kemeny, Nancy E., additional, Cercek, Andrea, additional, Connell, Louise Catherine, additional, Harding, James J., additional, Abou-Alfa, Ghassan K., additional, Park, Wungki, additional, Kingham, T. Peter, additional, Soares, Kevin, additional, Balachandran, Vinod P., additional, Drebin, Jeffrey A., additional, D'Angelica, Michael Ian, additional, O'Reilly, Eileen Mary, additional, Groot Koerkamp, Bas, additional, and Jarnagin, William R., additional

Published
2024
Full Text
View/download PDF

38. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma

Author

Chami, Perla, primary, Diab, Youssef, additional, Khalil, Danny N., additional, Azhari, Hassan, additional, Jarnagin, William R., additional, Abou-Alfa, Ghassan K., additional, Harding, James J., additional, Hajj, Joseph, additional, Ma, Jennifer, additional, El Homsi, Maria, additional, Reyngold, Marsha, additional, Crane, Christopher, additional, and Hajj, Carla, additional

Published
2023
Full Text
View/download PDF

39. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS

Author

Rose Brannon, A., Jayakumaran, Gowtham, Diosdado, Monica, Patel, Juber, Razumova, Anna, Hu, Yu, Meng, Fanli, Haque, Mohammad, Sadowska, Justyna, Murphy, Brian J., Baldi, Tessara, Johnson, Ian, Ptashkin, Ryan, Hasan, Maysun, Srinivasan, Preethi, Rema, Anoop Balakrishnan, Rijo, Ivelise, Agarunov, Aaron, Won, Helen, Perera, Dilmi, Brown, David N., Samoila, Aliaksandra, Jing, Xiaohong, Gedvilaite, Erika, Yang, Julie L., Stephens, Dennis P., Dix, Jenna-Marie, DeGroat, Nicole, Nafa, Khedoudja, Syed, Aijazuddin, Li, Alan, Lebow, Emily S., Bowman, Anita S., Ferguson, Donna C., Liu, Ying, Mata, Douglas A., Sharma, Rohit, Yang, Soo-Ryum, Bale, Tejus, Benhamida, Jamal K., Chang, Jason C., Dogan, Snjezana, Hameed, Meera R., Hechtman, Jaclyn F., Moung, Christine, Ross, Dara S., Vakiani, Efsevia, Vanderbilt, Chad M., Yao, JinJuan, Razavi, Pedram, Smyth, Lillian M., Chandarlapaty, Sarat, Iyer, Gopa, Abida, Wassim, Harding, James J., Krantz, Benjamin, O’Reilly, Eileen, Yu, Helena A., Li, Bob T., Rudin, Charles M., Diaz, Luis, Solit, David B., Arcila, Maria E., Ladanyi, Marc, Loomis, Brian, Tsui, Dana, Berger, Michael F., Zehir, Ahmet, and Benayed, Ryma

Published
2021
Full Text
View/download PDF

41. ASO Visual Abstract: Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma

Author

Franssen, Stijn, primary, Holster, Jessica J., additional, Jolissaint, Joshua S., additional, Nooijen, Lynn E., additional, Cercek, Andrea, additional, D’Angelica, Michael I., additional, Homs, Marjolein Y. V., additional, Wei, Alice C., additional, Balachandran, Vinod P., additional, Drebin, Jeffrey A., additional, Harding, James J., additional, Kemeny, Nancy E., additional, Kingham, T. Peter, additional, Klümpen, Heinz-Josef, additional, Mostert, Bianca, additional, Swijnenburg, Rutger-Jan, additional, Soares, Kevin C., additional, Jarnagin, William R., additional, and Groot Koerkamp, Bas, additional

Published
2023
Full Text
View/download PDF

42. Safety and Efficacy of Hepatic Artery Embolization in Heavily Treated Patients with Intrahepatic Cholangiocarcinoma: Analysis of Clinicopathological and Radiographic Parameters Associated with Better Overall Survival

Author

Velayati, Sara, primary, Elsakka, Ahmed, additional, Zhao, Ken, additional, Erinjeri, Joseph P., additional, Marinelli, Brett, additional, Soliman, Mohamed, additional, Chevallier, Olivier, additional, Ziv, Etay, additional, Brody, Lynn A., additional, Sofocleous, Constantinos T., additional, Solomon, Stephen B., additional, Harding, James J., additional, Abou-Alfa, Ghassan K., additional, D’Angelica, Michael I., additional, Wei, Alice C., additional, Kingham, Peter T., additional, Jarnagin, William R., additional, and Yarmohammadi, Hooman, additional

Published
2023
Full Text
View/download PDF

43. Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma

Author

Franssen, Stijn, primary, Holster, Jessica J., additional, Jolissaint, Joshua S., additional, Nooijen, Lynn E., additional, Cercek, Andrea, additional, D’Angelica, Michael I., additional, Homs, Marjolein Y. V., additional, Wei, Alice C., additional, Balachandran, Vinod P., additional, Drebin, Jeffrey A., additional, Harding, James J., additional, Kemeny, Nancy E., additional, Kingham, T. Peter, additional, Klümpen, Heinz-Josef, additional, Mostert, Bianca, additional, Swijnenburg, Rutger-Jan, additional, Soares, Kevin C., additional, Jarnagin, William R., additional, and Groot Koerkamp, Bas, additional

Published
2023
Full Text
View/download PDF

44. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma

Author

Cowzer, Darren, primary, White, Jessica B., additional, Chou, Joanne F., additional, Chen, Pin-Jung, additional, Kim, Tae-Hyung, additional, Khalil, Danny N., additional, El Dika, Imane H., additional, Columna, Katrina, additional, Yaqubie, Amin, additional, Light, Joseph S., additional, Shia, Jinru, additional, Yarmohammadi, Hooman, additional, Erinjeri, Joseph Patrick, additional, Wei, Alice C., additional, Jarnagin, William, additional, Do, Richard K.G., additional, Solit, David B., additional, Capanu, Marinela, additional, Shah, Ronak H., additional, Berger, Michael F., additional, Abou-Alfa, Ghassan K., additional, and Harding, James J., additional

Published
2023
Full Text
View/download PDF

45. In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors

Author

Khalil, Danny N., Suek, Nathan, Campesato, Luis Felipe, Budhu, Sadna, Redmond, David, Samstein, Robert M., Krishna, Chirag, Panageas, Katherine S., Capanu, Marinela, Houghton, Sean, Hirschhorn, Daniel, Zappasodi, Roberta, Giese, Rachel, Gasmi, Billel, Schneider, Michael, Gupta, Aditi, Harding, James J., Moral, John Alec, Balachandran, Vinod P., Wolchok, Jedd D., and Merghoub, Taha

Subjects
Bristol-Myers Squibb Co., Apoptosis -- Analysis, Cancer -- Analysis, Vaccination -- Analysis, Pharmaceutical industry -- Analysis, T cells -- Analysis, Biochemistry, Cell death, Tumors, Health care industry, Memorial Sloan-Kettering Cancer Center
Abstract

Irreversible T cell exhaustion limits the efficacy of programmed cell death 1 (PD-1) blockade. We observed that dual CD40-TLR4 stimulation within a single tumor restored PD-1 sensitivity and that this regimen triggered a systemic tumor-specific [CD8.sup.+] T cell response. This approach effectively treated established tumors in diverse syngeneic cancer models, and the systemic effect was dependent on the injected tumor, indicating that treated tumors were converted into necessary components of this therapy. Strikingly, this approach was associated with the absence of exhausted PD-[1.sup.hi] T cells in treated and distant tumors, while sparing the intervening draining lymph node and spleen. Furthermore, patients with transcription changes like those induced by this therapy experienced improved progression-free survival with anti-PD-1 treatment. Dual CD40-TLR4 activation within a single tumor is thus an approach for overcoming resistance to PD-1 blockade that is unique in its ability to cause the loss of exhausted T cells within tumors while sparing nonmalignant tissues., Introduction Immune checkpoint blockade (ICB) has improved outcomes for patients with diverse cancers, yet most patients with common cancers still do not show a clinical response. Features of malignant cells [...]

Published
2019
Full Text
View/download PDF

49. OncoTree: A Cancer Classification System for Precision Oncology

Author

Kundra, Ritika, Zhang, Hongxin, Sheridan, Robert, Sirintrapun, Sahussapont Joseph, Wang, Avery, Ochoa, Angelica, Wilson, Manda, Gross, Benjamin, Sun, Yichao, Madupuri, Ramyasree, Satravada, Baby A., Reales, Dalicia, Vakiani, Efsevia, Al-Ahmadie, Hikmat A., Dogan, Ahmet, Arcila, Maria, Zehir, Ahmet, Maron, Steven, Berger, Michael F., Viaplana, Cristina, Janeway, Katherine, Ducar, Matthew, Sholl, Lynette, Dogan, Snjezana, Bedard, Philippe, Surrey, Lea F., Sanchez, Iker Huerga, Syed, Aijaz, Rema, Anoop Balakrishnan, Chakravarty, Debyani, Suehnholz, Sarah, Nissan, Moriah, Iyer, Gopakumar V., Murali, Rajmohan, Bouvier, Nancy, Soslow, Robert A., Hyman, David, Younes, Anas, Intlekofer, Andrew, Harding, James J., Carvajal, Richard D., Sabbatini, Paul J., Abou-Alfa, Ghassan K., Morris, Luc, Janjigian, Yelena Y., Gallagher, Meighan M., Soumerai, Tara A., Mellinghoff, Ingo K., Hakimi, Abraham A., Fury, Matthew, Huse, Jason T., Bagrodia, Aditya, Hameed, Meera, Thomas, Stacy, Gardos, Stuart, Cerami, Ethan, Mazor, Tali, Kumari, Priti, Raman, Pichai, Shivdasani, Priyanka, MacFarland, Suzanne, Newman, Scott, Waanders, Angela, Gao, Jianjiong, Solit, David, and Schultz, Nikolaus

Published
2021
Full Text
View/download PDF

50. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

Author

Harding, James J, primary, Fan, Jia, additional, Oh, Do-Youn, additional, Choi, Hye Jin, additional, Kim, Jin Won, additional, Chang, Heung-Moon, additional, Bao, Lequn, additional, Sun, Hui-Chuan, additional, Macarulla, Teresa, additional, Xie, Feng, additional, Metges, Jean-Phillippe, additional, Ying, Jie'er, additional, Bridgewater, John, additional, Lee, Myung-Ah, additional, Tejani, Mohamedtaki A, additional, Chen, Emerson Y, additional, Kim, Dong Uk, additional, Wasan, Harpreet, additional, Ducreux, Michel, additional, Bao, Yuanyuan, additional, Boyken, Lisa, additional, Ma, Jiafang, additional, Garfin, Phillip, additional, Pant, Shubham, additional, Abou-Alfa, Ghassan, additional, Alfonso, Jorge Adeva, additional, Aglietta, Massimo, additional, Baron, Ari, additional, Beg, Muhammad, additional, Aguirre, Paula Carrasco, additional, Chen, Eric, additional, Cheng, Ying, additional, Gracián, Antonio Cubillo, additional, Dahan, Laetitia, additional, De Braud, Filippo, additional, Fenocchio, Elisabetta, additional, Gbolohon, Olumide, additional, Gillmore, Roopinder, additional, Jary, Marine, additional, Javle, Milind, additional, Jiang, Yixing, additional, Kang, Jung Hun, additional, King, Gentry George, additional, Kundranda, Madappa, additional, Layos, Laura, additional, Li, Daneng, additional, Liang, Tingbo, additional, Lonardi, Sara, additional, Marathe, Omkar, additional, Mondaca, Sebastian, additional, Martin, Andrés J. Muñoz, additional, Park, Joon Oh, additional, Pazo Cid, Roberto, additional, Fernandez, Paula Ribera, additional, Rimassa, Lorenza, additional, Alonso, Rosa Rodriguez, additional, Sadeghi, Saeed, additional, Scott, Aaron, additional, Tan, Benjamin, additional, Tougeron, David, additional, Yan, Qiang, additional, Yin, Xiaoyu, additional, and Zhao, Haitao, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results